Pancreatic ductal adenocarcinoma carries a dismal prognosis, and outcomes have
improved little with modern therapeutics. Checkpoint-based immunotherapy has failed to …

KRAS mutations are the drivers of various cancers, including non–small cell lung cancer,
colon cancer, and pancreatic cancer. Over the last 30 years, immense efforts have been …

Simple Summary Pancreatic cancer is the fourth leading cause of cancer-related mortality
worldwide. The poor survival associated with this disease is due to delayed diagnosis, a …

Pancreatic ductal adenocarcinoma is a devastating disease with a dismal prognosis.
Therapeutic interventions are largely ineffective. A better understanding of the …

Background To enhance the efficacy of adoptive NK cell therapy against solid tumors, NK
cells must be modified to resist exhaustion in the tumor microenvironment (TME). However …

Pancreatic cancer remains one of medicine's largest areas of unmet need. With five-year
survival rates of< 8%, little improvement has been made in the last 50 years. Typically …

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with poor outcomes due
to frequent recurrence, metastasis, and resistance to treatment. A major contributor to this …

The development of reprogramming technology to generate human induced pluripotent
stem cells (iPSCs) has tremendously influenced the field of regenerative medicine and …

Abstract Background and Objectives Pancreatic ductal adenocarcinoma (PDAC) is an
aggressive cancer with poor response to systemic therapies, including immunotherapy …

Aims To investigate the possible acute toxicities and pathological changes associated with
intravenous, intraperitoneal, or intratumoral injection of natural killer (NK) cells in mice …